Company news

Theralase Technologies Inc. news in 2026

Theralase Technologies Inc.'s news releases, calls and decks from 2026, newest first.

View company

Theralase Provides Bladder Cancer Clinical Study Update

October 26, 2026

Theralase(R) to Present at ThinkEquity Conference

October 9, 2026

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

September 18, 2026

Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)

September 15, 2026

Theralase(R) Releases Q2 2026 Financial Statements

August 28, 2026

Theralase(R) Closes C$3.6 Million Brokered Financing

August 24, 2026

Theralase(R) Announces $5 Million Brokered LIFE Offering

August 10, 2026

Theralase(R) Engages Global One Media to Expand Global Investor Awareness

August 4, 2026

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

June 30, 2026

Theralase(R) Lists Warrants on the TSXV

June 3, 2026

Theralase(R) Releases Q1 2026 Financial Statements

May 29, 2026

® Releases Q1 2026 Financial Statements

May 28, 2026

Theralase(R) Closes C$4.8 Million Offering

May 20, 2026

® Closes C$4.8 Million Offering

May 19, 2026

Theralase(R) Announces $4 Million Brokered LIFE Offering

May 5, 2026

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

May 4, 2026

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

April 13, 2026

Theralase(R) Closes $CAN 2.66 Million Financing

April 10, 2026

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

March 17, 2026

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

March 10, 2026

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

March 9, 2026

Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

March 2, 2026

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

February 20, 2026

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

February 17, 2026

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

February 10, 2026

Theralase(R) Provides Update on Bladder Cancer Clinical Study

February 4, 2026

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

February 2, 2026

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

January 12, 2026

Decks in 2026